Related Experiment Videos
Current topics in hepatitis B.
1Academic Centre for Travel Medicine and Vaccines, WHO Collaborating Centre for Reference and Research on Viral Diseases, Royal Free Campus, Royal Free and University College Medical School, London NW3 2PF, UK.
The Journal of Infection
|October 12, 2000
Summary
Hepatitis B virus (HBV) affects billions globally, leading to millions of deaths annually. This review covers HBV immunization, diagnostics, mutations, and new treatments for chronic infection and liver disease.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis B virus (HBV) infection is a major global health concern, with over 2 billion infected and 350 million chronic carriers.
- A significant portion of chronic carriers (25%) develop progressive liver disease, contributing to 1-2 million annual deaths worldwide.
Purpose of the Study:
- To review current strategies and challenges in managing hepatitis B infection.
- To provide an overview of recent advancements in HBV treatment and diagnostics.
Main Methods:
- Literature review of current topics in hepatitis B management.
- Analysis of immunization strategies, antibody kinetics, and immune response.
- Examination of blood donor screening controversies for anti-core antibodies.
- Review of hepatitis B surface antigen mutations and their detectability.
- Assessment of second-generation nucleoside analogues for chronic HBV treatment.
Main Results:
- Immunization strategies and antibody responses are critical for prevention.
- Controversies exist regarding anti-core antibody screening in blood donors.
- Hepatitis B surface antigen mutations may evade current diagnostic tests.
- Second-generation nucleoside analogues offer new treatment options for chronic HBV, including advanced liver disease and post-transplant patients.
Conclusions:
- Effective immunization and improved diagnostics are essential for controlling HBV.
- Further research is needed to address HBV mutations and optimize treatment strategies.
- Advancements in nucleoside analogue therapy improve outcomes for patients with chronic hepatitis B and liver complications.